Breaking News
-
Breaking News | Collaborations & Alliances | Drug Development
Jacobio Earns $20M AbbVie Milestone
Initiates Phase 1/2a trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib.06.18.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Eisai, BMS Enter Global Anticancer ADC Alliance
BMS to pay as much as $2.45B to co-develop Eisai’s MORAb-20206.18.21
-
Breaking News | Industry News | Laboratory Testing
-
Breaking News | Collaborations & Alliances | Industry News
KBI Biopharma, AM-Pharma Enter Manufacturing Agreement
Partnership supports future commercial manufacturing for AM-Pharma’s potential kidney disease treatment.06.17.21
-
Breaking News | Facilities | Industry News | Lyophilization
Horizon Therapeutics Buys EirGen Manufacturing Facility
The 44,000 square foot facility in Ireland includes fill-finish and analytical laboratory capabilities with potential for site expansion.06.17.21
-
Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Sanofi Invests $425M in Flu Vaccine Manufacturing Facility
Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.06.17.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Drug Discovery | Industry News
AbSci Acquires Cell Therapy Company Totient
Combination of Totient technology with AbSci's platform provides framework and data to enable in silico targeted drug design.06.17.21
-
Breaking News | Facilities
Thermo Scientific Upgrades Ultra-Low Temperature Freezers
The TSX Series ULT Freezers reliably preserve stored materials in an environmentally and user-friendly design.06.16.21
-
Breaking News | Collaborations & Alliances | Drug Development | Formulation Development
Lumen Bioscience, Novo Nordisk Enter Metabolic Research Pact
To explore Lumen's drug development and manufacturing platform to deliver oral biologics for cardiometabolic disease.06.16.21
-
Breaking News | Promotions & Moves | Solid Dosage/Creams/Ointments
-
Breaking News | Trials & Filings
REGEN-COV Phase 3 Trial Meets Primary Outcome
Improves survival by 20% in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2.06.16.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Facilities | Industry News
Dendreon Pharmaceuticals Establishes Contract Manufacturing Division
Now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.06.15.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News | Parenterals
Ocugen, Jubilant Enter COVID-19 Vaccine Partnership
Jubilant HollisterStier to manufacture COVAXIN for the U.S. and Canadian markets.06.15.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
VERAXA and Quadira Enter ADC Development Partnership
To develop a suite of novel ADCs for the treatment of oncological conditions.06.15.21
-
Breaking News | Facilities | Industry News
TriRx Pharmaceuticals Buys Elanco Sites
The CDMO is to purchase sites in Shawnee, KS and Speke, UK including planned transfer of 600 employees.06.15.21
-
Breaking News | Industry News | Solid Dosage/Creams/Ointments
Mikart Expands Oral Solids Production Capabilities
Acquires Korsch XM12 to meet client demands for complex formulation development and production of oral solid dose products.06.15.21
-
Breaking News | Industry News
GENinCode, EVERSANA Enter Major U.S. Commercialization Pact
EVERSANA will support launch and commercialization in the U.S. market for GENinCode’s portfolio of polygenic cardiovascular disease products.06.14.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Yposkesi to Build Second Commercial Bioproduction Site
Creates a new global resource for cell & gene therapy with production capacity for early clinical to commercially available biologics.06.14.21
-
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Trials & Filings
Novavax COVID-19 Vax is 90% Effective in Phase 3 Trial
NVX-CoV2373 demonstrates 100% protection against moderate and severe disease, 90% efficacy overall, and met the primary endpoint.06.14.21
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
iTeos Therapeutics, GSK Enter Monoclonal Antibody Alliance
GSK now has a leading portfolio of antibodies targeting the CD226 axis, a key target for next-gen immuno-oncology therapies06.14.21
